Founded in 2024, Kailera Therapeutics Inc. develops a portfolio of clinical-stage therapies targeting obesity and metabolic diseases. The company's lead candidate, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist currently in late-stage clinical trials. Kailera is also advancing a diversified pipeline that includes oral small molecule GLP-1 receptor agonists, such as KAI-7535, to provide varied treatment options for patients. The company's core assets were initially licensed from Jiangsu Hengrui Pharmaceuticals. Kailera operates primarily out of its facilities in Massachusetts and California.
